These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
252 related articles for article (PubMed ID: 25326896)
1. Expression and clinicopathological significance of EED, SUZ12 and EZH2 mRNA in colorectal cancer. Liu YL; Gao X; Jiang Y; Zhang G; Sun ZC; Cui BB; Yang YM J Cancer Res Clin Oncol; 2015 Apr; 141(4):661-9. PubMed ID: 25326896 [TBL] [Abstract][Full Text] [Related]
2. Overexpression of polycomb repressive complex 2 key components EZH2/SUZ12/EED as an unfavorable prognostic marker in cholangiocarcinoma. Wasenang W; Puapairoj A; Settasatian C; Proungvitaya S; Limpaiboon T Pathol Res Pract; 2019 Jul; 215(7):152451. PubMed ID: 31126817 [TBL] [Abstract][Full Text] [Related]
3. Statins inhibit tumor progression via an enhancer of zeste homolog 2-mediated epigenetic alteration in colorectal cancer. Ishikawa S; Hayashi H; Kinoshita K; Abe M; Kuroki H; Tokunaga R; Tomiyasu S; Tanaka H; Sugita H; Arita T; Yagi Y; Watanabe M; Hirota M; Baba H Int J Cancer; 2014 Dec; 135(11):2528-36. PubMed ID: 24346863 [TBL] [Abstract][Full Text] [Related]
4. Inhibition of enhancer of zeste homolog 2 (EZH2) expression is associated with decreased tumor cell proliferation, migration, and invasion in endometrial cancer cell lines. Eskander RN; Ji T; Huynh B; Wardeh R; Randall LM; Hoang B Int J Gynecol Cancer; 2013 Jul; 23(6):997-1005. PubMed ID: 23792601 [TBL] [Abstract][Full Text] [Related]
5. Activation of EZH2 and SUZ12 Regulated by E2F1 Predicts the Disease Progression and Aggressive Characteristics of Bladder Cancer. Lee SR; Roh YG; Kim SK; Lee JS; Seol SY; Lee HH; Kim WT; Kim WJ; Heo J; Cha HJ; Kang TH; Chung JW; Chu IS; Leem SH Clin Cancer Res; 2015 Dec; 21(23):5391-403. PubMed ID: 26268246 [TBL] [Abstract][Full Text] [Related]
6. PRC2-complex related dysfunction in overgrowth syndromes: A review of EZH2, EED, and SUZ12 and their syndromic phenotypes. Cyrus S; Burkardt D; Weaver DD; Gibson WT Am J Med Genet C Semin Med Genet; 2019 Dec; 181(4):519-531. PubMed ID: 31724824 [TBL] [Abstract][Full Text] [Related]
7. The role of EZH2 and DNA methylation in the silencing of the tumour suppressor RUNX3 in colorectal cancer. Kodach LL; Jacobs RJ; Heijmans J; van Noesel CJ; Langers AM; Verspaget HW; Hommes DW; Offerhaus GJ; van den Brink GR; Hardwick JC Carcinogenesis; 2010 Sep; 31(9):1567-75. PubMed ID: 20631058 [TBL] [Abstract][Full Text] [Related]
8. Aberrant differential expression of EZH1 and EZH2 in Polycomb repressive complex 2 among B- and T/NK-cell neoplasms. Abdalkader L; Oka T; Takata K; Sato H; Murakami I; Otte AP; Yoshino T Pathology; 2016 Aug; 48(5):467-82. PubMed ID: 27311868 [TBL] [Abstract][Full Text] [Related]
9. Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells. Fiskus W; Pranpat M; Balasis M; Herger B; Rao R; Chinnaiyan A; Atadja P; Bhalla K Mol Cancer Ther; 2006 Dec; 5(12):3096-104. PubMed ID: 17172412 [TBL] [Abstract][Full Text] [Related]
10. Ubiquitous expressed transcript promotes tumorigenesis by acting as a positive modulator of the polycomb repressive complex 2 in clear cell renal cell carcinoma. Zeng J; Xiang W; Zhang Y; Huang C; Chen K; Chen Z BMC Cancer; 2019 Sep; 19(1):874. PubMed ID: 31481081 [TBL] [Abstract][Full Text] [Related]
11. Enhancer of zeste homolog 2 (EZH2) promotes progression of cholangiocarcinoma cells by regulating cell cycle and apoptosis. Nakagawa S; Okabe H; Sakamoto Y; Hayashi H; Hashimoto D; Yokoyama N; Sakamoto K; Kuroki H; Mima K; Nitta H; Imai K; Chikamoto A; Watanabe M; Beppu T; Baba H Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S667-75. PubMed ID: 23887863 [TBL] [Abstract][Full Text] [Related]
12. EZH2 and STAT6 expression profiles are correlated with colorectal cancer stage and prognosis. Wang CG; Ye YJ; Yuan J; Liu FF; Zhang H; Wang S World J Gastroenterol; 2010 May; 16(19):2421-7. PubMed ID: 20480530 [TBL] [Abstract][Full Text] [Related]
13. Role of STAT3 and vitamin D receptor in EZH2-mediated invasion of human colorectal cancer. Lin YW; Ren LL; Xiong H; Du W; Yu YN; Sun TT; Weng YR; Wang ZH; Wang JL; Wang YC; Cui Y; Sun DF; Han ZG; Shen N; Zou W; Xu J; Chen HY; Cao W; Hong J; Fang JY J Pathol; 2013 Jul; 230(3):277-90. PubMed ID: 23424038 [TBL] [Abstract][Full Text] [Related]
15. Expression of the enhancer of zeste homolog 2 is correlated with poor prognosis in human gastric cancer. Matsukawa Y; Semba S; Kato H; Ito A; Yanagihara K; Yokozaki H Cancer Sci; 2006 Jun; 97(6):484-91. PubMed ID: 16734726 [TBL] [Abstract][Full Text] [Related]
16. Expression of the enhancer of zeste homolog 2 in biopsy specimen predicts chemoresistance and survival in advanced non-small cell lung cancer receiving first-line platinum-based chemotherapy. Xu C; Hao K; Hu H; Sheng Z; Yan J; Wang Q; Yu L Lung Cancer; 2014 Nov; 86(2):268-73. PubMed ID: 25262426 [TBL] [Abstract][Full Text] [Related]
17. Regulation of the expression of claudin 23 by the enhancer of zeste 2 polycomb group protein in colorectal cancer. Maryan N; Statkiewicz M; Mikula M; Goryca K; Paziewska A; Strzałkowska A; Dabrowska M; Bujko M; Ostrowski J Mol Med Rep; 2015 Jul; 12(1):728-36. PubMed ID: 25695204 [TBL] [Abstract][Full Text] [Related]
18. Aberrant expression of EZH2 is associated with pathological findings and P53 alteration. Shiogama S; Yoshiba S; Soga D; Motohashi H; Shintani S Anticancer Res; 2013 Oct; 33(10):4309-17. PubMed ID: 24122997 [TBL] [Abstract][Full Text] [Related]
19. Enhancer of zeste homolog 2 promotes the proliferation and invasion of epithelial ovarian cancer cells. Li H; Cai Q; Godwin AK; Zhang R Mol Cancer Res; 2010 Dec; 8(12):1610-8. PubMed ID: 21115743 [TBL] [Abstract][Full Text] [Related]
20. Downregulation of miR-193a-5p correlates with lymph node metastasis and poor prognosis in colorectal cancer. Zhang P; Ji DB; Han HB; Shi YF; Du CZ; Gu J World J Gastroenterol; 2014 Sep; 20(34):12241-8. PubMed ID: 25232258 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]